CD274 and neoplasm: Several biomarkers have been proposed to identify the predictability of response to PD-1 antagonists, including (i) > 1% of PD-L1+ tumor cells determined by immunohistochemistry, and (ii) microsatellite instability examination for the tumor cells deficient in mismatched DNA repair systems [58].